Exceptional response of lorlatinib and cabozantinib combination in ROS1-rearranged NSCLC
In this MEDtalk, Assistant Professor Tejas Patil presents a case with one of his patients having an exceptional response to lorlatinib and cabozantinib in ROS1-rearranged NSCLC with acquired F2004V and L2086F resistance.